InvestorsHub Logo
Followers 63
Posts 7608
Boards Moderated 1
Alias Born 01/02/2003

Re: None

Sunday, 05/01/2022 7:44:38 AM

Sunday, May 01, 2022 7:44:38 AM

Post# of 429367
"Announcing topline data from a Phase 2/3 study for Paxlovid, Pfizer (NYSE:PFE) said on Friday that the COVID-19 antiviral did NOT meet the main goal in the trial designed to evaluate its effect in the prevention of infection''

Perhaps a study on a combination of Vascepa and Paxlovid could achieve statistical significance in preventing Covid infections in patients who were in contact with people already infected with Covid.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News